Vitamin D

Cardiovascular Effects and Vascular Calcification

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Vitamin D plays a biphasic role in human health, with both intoxication and insufficiency compromising cardiovascular physiology. Dynamic interactions between the parathyroids, kidneys, and bone determine the toxicity threshold for vitamin D and calcium-i.e., whether hypervitaminosis D or excessive calcium intake is associated with cardiovascular toxicity. Age-dependent decline in renal function afflicts ∼25% of our population over age 60, and awareness of chronic renal insufficiency is very poor. Because vitamin D toxicities relate in part to abnormal serum and vascular calcium phosphate homeostasis recommended daily intakes of vitamin D and vitamin D agonist (vitamin D receptor (VDR) agonists, VDRAs) treatment should incorporate consideration of the common "renal frailty" of aging. Conversely, vitamin D insufficiency is associated with significant, undesirable changes in cardiovascular physiology and structure. As vasculotropic hormones, VDRAs have clear therapeutic roles in the setting of end-stage renal disease (ESRD); benefits relate in part to VDRA-mediated improvements in endothelial function via antiinflammatory actions, mitigation of the untoward cardiometabolic consequences of severe secondary hyperparathyroidism, and reductions in myocardial hypertrophic responses. Importantly, detailed physiological assessment of cardiovascular function has newly identified improvements in myocardial performance with vitamin D supplementation in patients with heart failure However, data demonstrating clinically significant cardiovascular benefit of vitamin D supplementation and/or VDRAs in individuals without ESRD are just as meager in 2016 as they were 2010. Much work remains to be done with respect to vitamin D and cardiometabolic physiology, but assiduous attention to the lessons learned hold tremendous promise to benefit human health and healthcare in our aging societies.

Original languageEnglish (US)
Title of host publicationHealth, Disease and Therapeutics
PublisherElsevier Inc.
Pages549-570
Number of pages22
Volume2
ISBN (Electronic)9780128099650
ISBN (Print)9780128099643
DOIs
StatePublished - Dec 14 2017

Fingerprint

Vascular Calcification
calcification
vitamin D
blood vessels
Vitamin D
agonists
Physiology
hypervitaminosis D
Cardiovascular Physiological Phenomena
Toxicity
physiology
kidneys
kidney diseases
Kidney
Chronic Kidney Failure
human health
Aging of materials
Health
hormone agonists
toxicity

Keywords

  • Arteriosclerosis
  • Cardiovascular disease
  • Cardiovascular remodeling
  • Heart failure
  • Nutrition
  • Toxicology

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Vitamin D : Cardiovascular Effects and Vascular Calcification. / Zechner, Christoph; Towler, Dwight A.

Health, Disease and Therapeutics. Vol. 2 Elsevier Inc., 2017. p. 549-570.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zechner, Christoph ; Towler, Dwight A. / Vitamin D : Cardiovascular Effects and Vascular Calcification. Health, Disease and Therapeutics. Vol. 2 Elsevier Inc., 2017. pp. 549-570
@inbook{3af81444422b4404beed4a2e6d249135,
title = "Vitamin D: Cardiovascular Effects and Vascular Calcification",
abstract = "Vitamin D plays a biphasic role in human health, with both intoxication and insufficiency compromising cardiovascular physiology. Dynamic interactions between the parathyroids, kidneys, and bone determine the toxicity threshold for vitamin D and calcium-i.e., whether hypervitaminosis D or excessive calcium intake is associated with cardiovascular toxicity. Age-dependent decline in renal function afflicts ∼25{\%} of our population over age 60, and awareness of chronic renal insufficiency is very poor. Because vitamin D toxicities relate in part to abnormal serum and vascular calcium phosphate homeostasis recommended daily intakes of vitamin D and vitamin D agonist (vitamin D receptor (VDR) agonists, VDRAs) treatment should incorporate consideration of the common {"}renal frailty{"} of aging. Conversely, vitamin D insufficiency is associated with significant, undesirable changes in cardiovascular physiology and structure. As vasculotropic hormones, VDRAs have clear therapeutic roles in the setting of end-stage renal disease (ESRD); benefits relate in part to VDRA-mediated improvements in endothelial function via antiinflammatory actions, mitigation of the untoward cardiometabolic consequences of severe secondary hyperparathyroidism, and reductions in myocardial hypertrophic responses. Importantly, detailed physiological assessment of cardiovascular function has newly identified improvements in myocardial performance with vitamin D supplementation in patients with heart failure However, data demonstrating clinically significant cardiovascular benefit of vitamin D supplementation and/or VDRAs in individuals without ESRD are just as meager in 2016 as they were 2010. Much work remains to be done with respect to vitamin D and cardiometabolic physiology, but assiduous attention to the lessons learned hold tremendous promise to benefit human health and healthcare in our aging societies.",
keywords = "Arteriosclerosis, Cardiovascular disease, Cardiovascular remodeling, Heart failure, Nutrition, Toxicology",
author = "Christoph Zechner and Towler, {Dwight A.}",
year = "2017",
month = "12",
day = "14",
doi = "10.1016/B978-0-12-809963-6.00084-5",
language = "English (US)",
isbn = "9780128099643",
volume = "2",
pages = "549--570",
booktitle = "Health, Disease and Therapeutics",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Vitamin D

T2 - Cardiovascular Effects and Vascular Calcification

AU - Zechner, Christoph

AU - Towler, Dwight A.

PY - 2017/12/14

Y1 - 2017/12/14

N2 - Vitamin D plays a biphasic role in human health, with both intoxication and insufficiency compromising cardiovascular physiology. Dynamic interactions between the parathyroids, kidneys, and bone determine the toxicity threshold for vitamin D and calcium-i.e., whether hypervitaminosis D or excessive calcium intake is associated with cardiovascular toxicity. Age-dependent decline in renal function afflicts ∼25% of our population over age 60, and awareness of chronic renal insufficiency is very poor. Because vitamin D toxicities relate in part to abnormal serum and vascular calcium phosphate homeostasis recommended daily intakes of vitamin D and vitamin D agonist (vitamin D receptor (VDR) agonists, VDRAs) treatment should incorporate consideration of the common "renal frailty" of aging. Conversely, vitamin D insufficiency is associated with significant, undesirable changes in cardiovascular physiology and structure. As vasculotropic hormones, VDRAs have clear therapeutic roles in the setting of end-stage renal disease (ESRD); benefits relate in part to VDRA-mediated improvements in endothelial function via antiinflammatory actions, mitigation of the untoward cardiometabolic consequences of severe secondary hyperparathyroidism, and reductions in myocardial hypertrophic responses. Importantly, detailed physiological assessment of cardiovascular function has newly identified improvements in myocardial performance with vitamin D supplementation in patients with heart failure However, data demonstrating clinically significant cardiovascular benefit of vitamin D supplementation and/or VDRAs in individuals without ESRD are just as meager in 2016 as they were 2010. Much work remains to be done with respect to vitamin D and cardiometabolic physiology, but assiduous attention to the lessons learned hold tremendous promise to benefit human health and healthcare in our aging societies.

AB - Vitamin D plays a biphasic role in human health, with both intoxication and insufficiency compromising cardiovascular physiology. Dynamic interactions between the parathyroids, kidneys, and bone determine the toxicity threshold for vitamin D and calcium-i.e., whether hypervitaminosis D or excessive calcium intake is associated with cardiovascular toxicity. Age-dependent decline in renal function afflicts ∼25% of our population over age 60, and awareness of chronic renal insufficiency is very poor. Because vitamin D toxicities relate in part to abnormal serum and vascular calcium phosphate homeostasis recommended daily intakes of vitamin D and vitamin D agonist (vitamin D receptor (VDR) agonists, VDRAs) treatment should incorporate consideration of the common "renal frailty" of aging. Conversely, vitamin D insufficiency is associated with significant, undesirable changes in cardiovascular physiology and structure. As vasculotropic hormones, VDRAs have clear therapeutic roles in the setting of end-stage renal disease (ESRD); benefits relate in part to VDRA-mediated improvements in endothelial function via antiinflammatory actions, mitigation of the untoward cardiometabolic consequences of severe secondary hyperparathyroidism, and reductions in myocardial hypertrophic responses. Importantly, detailed physiological assessment of cardiovascular function has newly identified improvements in myocardial performance with vitamin D supplementation in patients with heart failure However, data demonstrating clinically significant cardiovascular benefit of vitamin D supplementation and/or VDRAs in individuals without ESRD are just as meager in 2016 as they were 2010. Much work remains to be done with respect to vitamin D and cardiometabolic physiology, but assiduous attention to the lessons learned hold tremendous promise to benefit human health and healthcare in our aging societies.

KW - Arteriosclerosis

KW - Cardiovascular disease

KW - Cardiovascular remodeling

KW - Heart failure

KW - Nutrition

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=85054938671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054938671&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-809963-6.00084-5

DO - 10.1016/B978-0-12-809963-6.00084-5

M3 - Chapter

SN - 9780128099643

VL - 2

SP - 549

EP - 570

BT - Health, Disease and Therapeutics

PB - Elsevier Inc.

ER -